Lung Diseases, Interstitial

The grounding supports both idiopathic and known-cause forms of interstitial lung disease. It specifically includes chemically induced disease, such as drug-related interstitial lung disease/pneumonitis associated with trastuzumab deruxtecan. It also supports interstitial lung disease associated with rheumatoid arthritis as a disease-related cause.

The core process is initial inflammation in the pulmonary alveoli with extension into the interstitium and beyond. This inflammatory injury can lead to diffuse pulmonary fibrosis. In rheumatoid arthritis-associated interstitial lung disease, the literature also emphasizes evolving concepts in pulmonary fibrosis pathogenesis.

The grounding supports rheumatoid arthritis as a condition associated with interstitial lung disease, particularly rheumatoid arthritis-associated ILD. Exposure to trastuzumab deruxtecan is a risk for drug-related interstitial lung disease/pneumonitis. The supplied material does not support additional risk factors.

Management is described at the level of diagnosis and drug therapy rather than specific regimens. For drug-related interstitial lung disease/pneumonitis, the literature emphasizes proactive monitoring, diagnosis of exclusion, and management of the adverse event. For rheumatoid arthritis-associated interstitial lung disease, the review notes therapeutic strategies and a rational clinical approach to diagnosis and management, but the supplied grounding does not support specific treatment classes beyond general management.